Brexit and British Biotech
I have a tool that can be used to measure the impact of Brexit on biotechnology in the United Kingdom. […]
General Biotechnology
Mainstreaming the Microbiome – Part 2
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
FDA Orange Book Archives From 1980 to Present
DrugPatentWatch offers PDF copies of the FDA Orange Book dating back to 1980. The Food and Administration (FDA) Orange Book, or Approved
General Biotechnology
Get your Worldview on — Measuring Global Biotechnology at #BIO2016
On Thursday June 9th from 10:30 to 11:30pm in Room 124 North Mike May and I will be going over the
Get your Worldview on — Measuring Global Biotechnology at #BIO2016 Read Post »
General Biotechnology
Come to my book signing at #BIO2016
I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Wednesday June 8th from 12:30 pm
General Biotechnology
Biotech in Countries Starting with “I” – Part 10: India
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Biotech in Countries Starting with “I” – Part 10: India Read Post »
Biosimilar Naming: Distinguishable or Disingenuous?
This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a
Biosimilar Naming: Distinguishable or Disingenuous? Read Post »
Featured, General Biotechnology
When do Drug Patents Expire, and When Can Generic Drugs Launch?
[slideshare id=61425574&doc=whendodrugpatentsexpire-160427163211] When do drug patents expire, and when can generic drugs launch? An overview of patents, non-patent regulatory exclusivities,
When do Drug Patents Expire, and When Can Generic Drugs Launch? Read Post »
Mainstreaming the Microbiome
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Which pharmaceutical companies have the most “New Dosage Form” drugs?
New Dosage Forms are one of the categories for which the FDA grants three years of exclusivity for ‘New Clinical
Which pharmaceutical companies have the most “New Dosage Form” drugs? Read Post »